Is the combination protocol right for your grade of osteoarthritis?

Kellgren-Lawrence Grade III or IV means the cartilage surfaces are substantially worn and the joint shows clear radiological change — a stage at which joint replacement is often the first option a patient is offered. The CFI+ combination protocol sits in a narrower window than that framing suggests: it is designed for advanced osteoarthritis that has not yet consumed every avenue for preservation.

The gateway to combination therapy is MRI, not a pain score. A clinician reading that scan is looking at two specific questions: what is the pattern and extent of cartilage loss, and is there active synovitis? Both must be present and must fit the right morphology before the dual-injection approach is warranted. Patient preference and symptom severity alone do not determine the pathway.

The patient profile where combination therapy is most defensible is broadly a younger or middle-aged adult with MRI-confirmed focal-to-moderate cartilage loss alongside synovitis — reflected in rest pain, recurrent swelling, or inflammatory episodes — who wants to preserve the joint before committing to replacement. In this group, ChondroFiller addresses the worn bone surfaces while Arthrosamid targets the inflamed synovial lining: two anatomically distinct problems treated in a single outpatient appointment, with no surgery and no general anaesthetic.

Patients whose imaging shows purely diffuse, end-stage wear across the entire joint surface are less likely to respond well. The published evidence for the ChondroFiller scaffold is strongest for contained, focal lesions; that limitation holds even within the combination protocol.

Why Grade III–IV osteoarthritis is a two-problem disease

The joint damage in Grade III–IV osteoarthritis accumulates along two separate fronts. At the load-bearing surfaces — the ends of the femur and tibia — articular cartilage has worn to the point where bone is exposed or nearly so, creating mechanical dysfunction with every step. Simultaneously, the synovial membrane lining the joint capsule becomes chronically inflamed. That inflamed lining generates destructive enzymes and signalling molecules that degrade remaining cartilage, sustain pain, and drive the recurrent swelling many patients describe as a constant feature of daily life.

These two processes are anatomically distinct. Targeting the cartilage surface alone — without addressing the synovium — leaves the inflammatory source intact, continuing to work against whatever repair the surface intervention achieves. Targeting the synovium alone does nothing to restore the articulating surface that has already been lost.

This is why the CFI+ protocol pairs two agents performing fundamentally different roles: the ChondroFiller injection works at the cartilage surface, providing an acellular collagen scaffold that supports new matrix formation; Arthrosamid integrates into the synovial lining to cushion and calm it from within. Combining them is not a matter of doing more for the sake of it — it reflects the clinical recognition that advanced OA is two simultaneous problems occupying the same joint. A single viscosupplement or corticosteroid injection addresses neither pathological process completely, which is what distinguishes a dual-target strategy from conventional single-modality injection care.

How the ChondroFiller injection addresses cartilage loss

Delivered as an ultrasound-guided outpatient injection, ChondroFiller is a Type I collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany. Once injected onto the worn cartilage surface, it polymerises in situ within approximately 3–5 minutes, filling the defect without the need for drilling, microfracturing, or fibrin glue.

What happens over the following months is the mechanism that matters. Because the scaffold is acellular — it contains no donor cells — it works by recruiting the patient's own progenitor cells from surrounding synovial tissue and subchondral bone. Those cells migrate into the matrix and gradually deposit new tissue over 6–12 months. This is acellular matrix-induced chondrogenesis: the collagen scaffold creates the structured environment; the patient's biology does the repair work. It supports the body's own regenerative processes rather than substituting for them.

The strongest published evidence comes from a prospective cohort by Mazek (2021, PMC; n=26, follow-up 12–60 months), which recorded MRI-confirmed cartilage healing and found 17 of 21 evaluable patients reporting good or excellent outcomes at three to five years. That figure carries an important caveat, however: patients with pre-existing generalised osteoarthritis — Tönnis Grade 2 or 3 — had poor results in the same study. The scaffold performs best where cartilage loss is focal and reasonably contained, not where wear has spread diffusely across the joint surface.

This is precisely where the combination rationale enters. Arthrosamid's role in cushioning and calming the synovial lining may reduce the inflammatory burden on the repair site, potentially creating a more permissive biological environment for matrix-induced chondrogenesis to take hold. That specific interaction is biologically plausible, but it has not yet been confirmed by a randomised controlled trial of the co-delivered protocol in KL Grade III–IV knees.

What Arthrosamid contributes at the synovial level

Arthrosamid is a different material with a different purpose. Composed of 97.5% water cross-linked around a 2.5% polyacrylamide framework, it is not a regenerative scaffold — it is a permanent mechanical cushion injected into the synovial lining of the joint capsule.

After a single injection, it integrates sub-synovially within 10 to 14 days. Animal histopathological studies confirm that by day 30 in horses and day 90 in rabbits, a stable sub-synovial layer had formed, traversed by connective tissue and covered by synovial cells facing the joint cavity — a configuration that persisted up to two years. The process has been characterised as a low-level macrophage-driven foreign body response, not inflammation in the damaging sense.

The pain data are notable: real-world evidence records significant pain reduction maintained up to five years after a single injection. More intriguing is a 2022 paper by Maulana, Cole, and Lee in the Journal of Arthritis, which found reduction in patellofemoral bone marrow lesions following a single iPAAG injection in advanced osteoarthritis — a finding that suggests the benefit may extend beyond symptom relief to some measurable structural effect, though the mechanism behind that observation has not yet been fully characterised.

In the CFI+ combination protocol, Arthrosamid's contribution is specific and bounded: it addresses the synovial lining, reduces the inflammatory environment, and provides mechanical cushioning for the joint capsule wall. Repairing the articular cartilage surface is not its role — that remains the ChondroFiller injection's domain. The two agents are not interchangeable; one is a regenerative scaffold, the other a hydrogel implant. Using both together means both jobs are being covered, not that either is being used twice.

What the evidence currently shows — and where gaps remain

The evidence gap in the CFI+ protocol has a specific shape, and naming it clearly is more useful than either glossing over it or treating it as a reason not to proceed.

Both constituent agents have independent published data supporting them — the Mazek 2021 cohort for ChondroFiller and the five-year real-world pain data plus Maulana and colleagues' 2022 structural finding for Arthrosamid, both covered in the preceding sections. What does not yet exist is a randomised controlled trial examining the co-delivered combination in KL Grade III–IV knees as a single study. The combination rationale is currently mechanism-based inference plus those independent observational signals, not a purpose-designed combination trial. That is not unusual — most combination approaches in regenerative medicine reach clinical use before combination-specific RCTs are complete — but it is the accurate position and it has a practical implication for how a patient should think about the decision.

The unresolved tension is whether ChondroFiller's benefit can extend meaningfully into moderately advanced disease when Arthrosamid's synovial cushioning reduces the inflammatory burden on the repair site. The claim is biologically coherent. Whether it is borne out across the full range of KL III–IV presentations — from moderate focal wear through to near-total surface destruction — remains the open question.

For a patient deciding now, the evidence gap becomes more or less acceptable depending on how closely the MRI matches the profile where each agent's data actually applies: focal, identifiable cartilage loss with MRI-confirmed synovitis, not diffuse end-stage destruction. Where the scan shows that profile, both components have independent evidence that speaks directly to the clinical problem. Where wear is diffuse and the joint space largely obliterated, the combination's benefit is harder to argue from current data. The scan, not the pain score alone, is what determines whether the evidence gap is a reasonable one to bridge.

Assessment, what the appointment involves, and access in London

Accessing the CFI+ protocol starts with imaging. Before the combination is recommended, an MRI confirms two things: the pattern and extent of cartilage loss, and the presence and character of synovitis. That scan-first sequence means both components of the protocol are individually justified by what the imaging shows — not applied as a package on the basis of symptom severity alone.

For patients who meet those imaging criteria, both injections are given in a single outpatient appointment, with no surgery and no general anaesthetic. ChondroFiller injection (2.3 mL) is placed onto the worn bone surfaces; Arthrosamid (6 mL) is injected into the synovial lining. Neither requires a hospital stay.

The guide cost for the combination is approximately £6,000, to be confirmed with the treating clinic. Neither product is available on the NHS, and neither is currently covered by major UK private medical insurers including Bupa and AXA; both are accessed on a self-funded basis. For cases of particularly severe joint compromise, the Tri-Active Therapy — which adds autologous mesenchymal stem cells to the dual-injection framework as a third layer, targeting cellular signalling alongside structural repair and synovial cushioning — is available at approximately £11,000. The standard two-component CFI+ protocol is the usual starting point for most patients at this stage.

In the UK, ChondroFiller injection is delivered through the London Cartilage Clinic on Harley Street, the UK certified centre for the treatment; assessment including MRI review is arranged via londoncartilage.com. Before any appointment, the most useful preparation is a clear account of what previous imaging has shown and which treatments have already been tried.